1. Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial;Wei;Ann Rheum Dis,2021
2. Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials
3. Bausch Health Americas, Inc . “A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3,” clinicaltrials.gov, Clinical trial registration study/NCT01708629 , 2019. Available: https://clinicaltrials.gov/ct2/show/study/NCT01708629 [Accessed May 06, 2021].
4. Bausch Health Americas, Inc . “A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2,” clinicaltrials.gov, Clinical trial registration results/NCT01708603 , 2020. Available: https://clinicaltrials.gov/ct2/show/results/NCT01708603 [Accessed May 06, 2021].
5. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial;Deodhar;The Lancet,2020